It is a 4-nitrogen steroid hormone compound and a specific type II 5alpha;-reductase competitive inhibitor. It inhibits the conversion of peripheral testosterone into dihydrotestosterone and reduces the level of dihydrotestosterone in the blood, prostate, skin and other tissues. It inhibits prostate hyperplasia and improves the clinical symptoms related to benign prostatic hyperplasia by reducing the level of dihydrotestosterone in the blood and prostate tissue.

This product is a first-generation cephalosporin, which has good antibacterial effect on some strains of Gram-positive cocci such as non-penicillinase-producing and penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococci, group A hemolytic Streptococcus, Streptococcus pneumoniae and viridans Streptococcus. Anaerobic Gram-positive bacteria are mostly sensitive to this product, and Bacteroides fragilis is resistant to this product. Methicillin-resistant Staphylococci and Enterococci are resistant to this product. The effect of this product on Gram-positive and Gram-negative bacteria is similar to that of cephalexin. This product has a certain effect on Neisseria gonorrhoeae, and is also active against enzyme-producing Neisseria gonorrhoeae; its activity against Haemophilus influenzae is poor. The mechanism of action is to inhibit the synthesis of bacterial cell walls.

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

Nimodipine is a Ca2 channel blocker that inhibits smooth muscle contraction and relieves vasospasm by preventing Ca2 from entering cells. It has a strong effect on cerebral arteries and is lipophilic and can easily penetrate the blood-brain barrier. It can be used to prevent vasospasm after subarachnoid hemorrhage and also has the effect of protecting and promoting memory.

Telmisartan is an orally effective, specific angiotensin II receptor (AT1 type) antagonist that binds to the angiotensin II receptor AT1 subtype with high affinity. The binding effect is long-lasting, but without any partial agonist effect. Telmisartan can cause a decrease in blood aldosterone levels, does not inhibit human plasma renin, and does not block ion channels. Since telmisartan does not inhibit angiotensin converting enzyme, there will be no adverse reactions caused by enhanced bradykinin effects. Telmisartan has no affinity for other receptors (including AT2 and other AT receptors with fewer characteristics). Telmisartan can reduce systolic and diastolic blood pressure without affecting heart rate.